These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 9485024)

  • 21. Morphology reversion activity of phosmidosine and phosmidosine B, a newly isolated derivative, on src transformed NRK cells.
    Matsuura N; Onose R; Osada H
    J Antibiot (Tokyo); 1996 Apr; 49(4):361-5. PubMed ID: 8641999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin D1 as a proliferative marker regulating retinoblastoma phosphorylation in mouse lung epithelial cells.
    Mamay CL; Schauer IE; Rice PL; McDoniels-Silvers A; Dwyer-Nield LD; You M; Sclafani RA; Malkinson AM
    Cancer Lett; 2001 Jul; 168(2):165-72. PubMed ID: 11403921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock.
    Zhang Y; Giacchetti S; Parouchev A; Hadadi E; Li X; Dallmann R; Xandri-Monje H; Portier L; Adam R; Lévi F; Dulong S; Chang Y
    Cell Cycle; 2018; 17(1):33-42. PubMed ID: 29099263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First synthesis and anticancer activity of phosmidosine and its related compounds.
    Moriguchi T; Asai N; Okada K; Seio K; Sasaki T; Sekine M
    J Org Chem; 2002 May; 67(10):3290-300. PubMed ID: 12003538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening of cell cycle inhibitors from microbial metabolites by a bioassay using a mouse cdc2 mutant cell line, tsFT210.
    Osada H; Cui CB; Onose R; Hanaoka F
    Bioorg Med Chem; 1997 Jan; 5(1):193-203. PubMed ID: 9043671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Turning cell cycle entry on its head.
    Bertoli C; de Bruin RA
    Elife; 2014 Jul; 3():e03475. PubMed ID: 24986860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and application of bioprobes for Mammalian cell cycle analyses.
    Osada H
    Curr Med Chem; 2003 May; 10(9):727-32. PubMed ID: 12678775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological properties of stable phosmidosine analogs.
    Okada K; Taguchi H; Seio K; Kakeya H; Osada H; Sasaki T; Sekine M
    Nucleic Acids Res Suppl; 2003; (3):105-6. PubMed ID: 14510402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commentary: locating the restriction point.
    Brooks RF
    Cell Div; 2023 Feb; 18(1):2. PubMed ID: 36765359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restriction point regulation at the crossroads between quiescence and cell proliferation.
    Pennycook BR; Barr AR
    FEBS Lett; 2020 Jun; ():. PubMed ID: 32564372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restriction beyond the restriction point: mitogen requirement for G2 passage.
    Foijer F; Te Riele H
    Cell Div; 2006 May; 1():8. PubMed ID: 16759363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The restriction point and control of cell proliferation.
    Planas-Silva MD; Weinberg RA
    Curr Opin Cell Biol; 1997 Dec; 9(6):768-72. PubMed ID: 9425340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Putting Rb in context with JNK.
    Stronach B
    Cell Cycle; 2015; 14(24):3783. PubMed ID: 26697834
    [No Abstract]   [Full Text] [Related]  

  • 34. Discovery and applications of nucleoside antibiotics beyond polyoxin.
    Osada H
    J Antibiot (Tokyo); 2019 Dec; 72(12):855-864. PubMed ID: 31554959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells.
    Sun Y; Li YX; Wu HJ; Wu SH; Wang YA; Luo DZ; Liao DJ
    J Cancer; 2011 Jan; 2():36-51. PubMed ID: 21234300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein.
    Jain HD; Zhang C; Zhou S; Zhou H; Ma J; Liu X; Liao X; Deveau AM; Dieckhaus CM; Johnson MA; Smith KS; Macdonald TL; Kakeya H; Osada H; Cook JM
    Bioorg Med Chem; 2008 Apr; 16(8):4626-51. PubMed ID: 18321710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells.
    Fukuoka K; Usuda J; Iwamoto Y; Fukumoto H; Nakamura T; Yoneda T; Narita N; Saijo N; Nishio K
    Invest New Drugs; 2001; 19(3):219-27. PubMed ID: 11561678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic.
    Kakeya H; Onose R; Liu PC; Onozawa C; Matsumura F; Osada H
    Cancer Res; 1998 Feb; 58(4):704-10. PubMed ID: 9485024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression.
    Kitagawa M; Higashi H; Takahashi IS; Okabe T; Ogino H; Taya Y; Hishimura S; Okuyama A
    Oncogene; 1994 Sep; 9(9):2549-57. PubMed ID: 8058318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An anchorage-dependent signal distinct from p42/44 MAP kinase activation is required for cell cycle progression.
    Le Gall M; Grall D; Chambard JC; Pouysségur J; Van Obberghen-Schilling E
    Oncogene; 1998 Sep; 17(10):1271-7. PubMed ID: 9771970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.